GLP-1 RAs produce significant weight loss in adults without diabetes, with newer treatments showing greater results
An updated systematic review evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and coagonists among adults with overweight or obesity without diabetes found that, among currently available treatments, tirzepatide produced the greatest weight loss, while newer experimental drugs showed even larger effects.
A new systematic review found that GLP-1 receptor agonists (GLP-1 RAs) and coagonists significantly reduce weight in adults with obesity or overweight who do not have diabetes. Among the currently available treatments, tirzepatide demonstrated the most substantial weight loss, while newer experimental drugs showed even greater effects.
The review, published in Annals of Internal Medicine, analyzed data from 38 randomized controlled trials involving 25,816 adults. GLP-1 RAs led to weight loss ranging from over 20% of body weight to less than 5%, with gastrointestinal side effects being the most common adverse effect. Serious adverse events and deaths were rare, with no new safety concerns identified.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
